EDL6D
NASH (Non-alcoholic steatohepatitis)
PreclinicalActive
Key Facts
Indication
NASH (Non-alcoholic steatohepatitis)
Phase
Preclinical
Status
Active
Company
About EndoLipiD Therapeutics
EndoLipiD Therapeutics is a private, preclinical-stage biotech leveraging a novel mechanism of action—mimicking the endogenous protein SHBG—to address diseases of ectopic fat accumulation. Its lead program, EDL6D, targets NASH with demonstrated efficacy in reducing liver fat, inflammation, and fibrosis in animal models, while a second program, EDL81 (Ac-EDL67), for cellulite is in co-development with Nanovex Biotechnologies. The company is supported by venture capital, public grants including EU Next Generation funds, and a crowdfunding campaign, and is led by a team combining deep scientific expertise in SHBG biology with clinical and business development experience.
View full company profileTherapeutic Areas
Other NASH (Non-alcoholic steatohepatitis) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Internal Program | Viscient Biosciences | Preclinical |
| Undisclosed In-licensed Program | Viscient Biosciences | Phase 2 |
| ALN-HSD | Alnylam Pharmaceuticals | Phase 1 |